TFS Financial Corp.

超10亿美元！罗氏达成抗体降解剂偶联物研发合作 近日，C4 Therapeutics宣布与罗氏（Roche）达成新的合作协议，双方将共同推进新兴治疗模式抗体降解剂偶联物（degrader-antibody conjugate，DAC）的研究。该策略结合了抗体偶联药物（ADC）的精准递送能力与靶向蛋白降解（TPD）技术的催化式作用机制，旨在通过抗体将降解剂精准递送至肿瘤细胞，从而实现对致病蛋白的选择性降解，为癌症治疗提供新的技术路径。 根据双方的联合研究计划，两家公司将围绕两个尚未披露的肿瘤靶点开展DAC项目开发。C4 Therapeutics将利用其专有的TORPEDO平台设计降解剂载荷候选分子，而罗氏则负责抗体的选择与设计，并完成抗体与降解剂载荷的偶联。此外，罗氏还将负责推动相关DAC候选药物进入临床前研究、临床开发及后续商业化。根据协议条款，C4 Therapeutics将获得2000万美元的预付款，并有资格获得超过10亿美元的研发、监管及商业化里程碑付款等款项。 5400万美元A轮融资！新锐布局肝外靶向RNA疗法 Vivatides Therapeutics今日宣布完成超额认购的5400万美元A轮融资。本轮融资由Qiming Venture Partners与一家行业基金共同领投，Highlight Capital和TF Capital参与投资，现有投资者Apricot Capital也继续追加投资。公司表示，本轮融资所得资金将用于进一步推进其肝外RNA递送平台建设，加速多个管线项目进入临床开发阶段，并扩展全球团队及研发网络。 Vivatides成立于2025年，专注于自主肝外RNA递送技术的创新与转化。公司核心管理团队拥有丰富的RNA药物研发经验，曾在多家RNA疗法企业中主导或参与多个肝外RNA项目，其中部分项目已进入临床开发阶段。依托这一经验，公司构建了差异化的肝外递送平台，覆盖siRNA和反义寡核苷酸（ASO）两类技术路线，并在配体偶联、递送效率、组织靶向特异性以及安全性等方面取得重要进展，已获得具有潜力的体内研究结果。结合序列设计和靶点发现能力，该平台能够支持多条管线并行推进。未来，公司计划利用本轮融资加速临床前优化和IND支持研究，进一步扩展研发与管理团队，并持续完善其肝外递送平台，推动RNA疗法在高患病率肝外疾病领域的应用。 参考资料： [1] C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs). Retrieved April 10, 2026 from https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-expands-long-term-partnership-roche-through-new [2] Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development. Retrieved April 10, 2026 from https://www.prnewswire.com/news-releases/vivatides-therapeutics-announces-oversubscribed-54-million-series-a-financing-to-accelerate-extrahepatic-rna-therapeutics-development-302738127.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

Boasting the ability to deliver RNA therapeutics into areas outside the liver, Vivatides Therapeutics on Friday raised an oversubscribed $54-million series A, less than a year after its 2025 founding.Despite the modality's promise of high specificity, durability and efficacy, challenges with delivery have largely limited RNA therapeutics to liver-targeted applications."Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications," Vivatides founder Keming Zhou said in a company release. "We believe that overcoming delivery barriers will enable RNA therapeutics to transform treatment paradigms across a wide range of diseases."To go beyond the liver, Vivatides said it has advanced several key technologies behind RNA therapeutics, including ligand conjugation, sequence design and target discovery, to improve tissue targeting specificity, delivery efficiency and safety. The company emphasised that its  extrahepatic delivery platform is compatible with both siRNA and antisense oligonucleotides. By reaching extrahepatic targets, Vivatides thinks RNA therapeutics can move beyond rare diseases and help treat chronic conditions like hyperlipidemia, hypertension and oncology.Friday's financing, co-led by Qiming Venture Partners, will enable preclinical optimisation and IND-enabling activities for Vivatides' pipeline, support the expansion of its R&D and management teams, and help the biotech further build out its delivery platform. Highlight Capital, TF Capital and existing investor Apricot Capital also participated in the round. Qiming also participated in Vivatides' $10-million seed round, according to a LinkedIn post from the VC in September 2025.

Vivatides Therapeutics, a biotechnology company with operations in Woburn, Massachusetts and Suzhou, China focused on extrahepatic RNA-targeting therapeutics, has closed an oversubscribed USD 54 million Series A financing round to advance its RNA delivery platform beyond liver-targeted applications. The round was co-led by Qiming Venture Partners and an unnamed industry fund, with participation from Highlight Capital, TF Capital, and existing seed investor Apricot Capital. Proceeds will be directed +toward advancing the company’s extrahepatic delivery platform, progressing multiple pipeline programs toward clinical development, and expanding its global research and development network. Vivatides said it completed both its seed round — reported at approximately USD 10 million and led by Apricot Capital — and the Series A within less than one year of the company’s founding in 2025. The company’s pipeline remains preclinical, with the Series A proceeds earmarked for IND-enabling studies across programs spanning two modalities: small interfering RNA (siRNA) and antisense oligonucleotides (ASOs). Vivatides has cited hyperlipidemia, hypertension, and oncology as target disease areas, positioning itself to pursue high-prevalence chronic conditions rather than the rare disease indications that have historically characterized the RNA therapeutics field. No named drug candidates or specific molecular targets have been publicly disclosed. The scientific rationale for the platform centers on a delivery problem that has constrained RNA therapeutics since the modality’s earliest clinical applications. Approved siRNA drugs have largely relied on GalNAc conjugation to direct molecules to the liver via the asialoglycoprotein receptor, a strategy that exploits the liver’s unique anatomical accessibility. Vivatides is building around ligand conjugation approaches designed to direct siRNA and ASO molecules to non-hepatic cell types through receptor-mediated endocytosis, aiming to replicate the liver-targeting logic for extrahepatic tissues. The company said it has achieved advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and chemical stability, with in vivo results already generated. Keming Zhou, who founded Vivatides, leads the company. The press release describes the leadership team as drawing on experience from established RNA therapeutics organizations, with members said to have previously contributed to extrahepatic RNA programs that reached clinical development. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website